-transparent.png){kind=logo}
Fifteen patients with chronic type B hepatitis were treated with corticosteroids in a randomized, double-blind, placebo-controlled trial lasting 28 days. Ten patients received prednisolone, 60 mg/d for 2 weeks, then 30 mg/d for another 2 weeks; 5 patients received placebo. Serum aminotransferase levels decreased significantly during prednisolone therapy but 4 to 10 weeks after abrupt withdrawal of the drug, they rebounded to levels greater than those before treatment. This exacerbation of disease lasted for several months and was prolonged and symptomatic in 3 patients. Hepatitis B virus levels did not change substantially during treatment. Follow-up examinations showed no improvement in biochemical or serologic features of the disease in any of the 15 patients; follow-up liver biopsies showed a worsening in 4 of 7 treated patients but in 0 of 5 control patients. Thus, a 28-day course of prednisolone produced no beneficial effects in patients with mild-to-moderate chronic type B hepatitis; on the contrary, such treatment may be harmful.
J H Hoofnagle, and
G L Davis, and
S C Pappas, and
R G Hanson, and
M Peters, and
M I Avigan, and
J G Waggoner, and
E A Jones, and
L B Seeff
October 2011,
Epilepsia,
J H Hoofnagle, and
G L Davis, and
S C Pappas, and
R G Hanson, and
M Peters, and
M I Avigan, and
J G Waggoner, and
E A Jones, and
L B Seeff
November 2003,
World journal of gastroenterology,
J H Hoofnagle, and
G L Davis, and
S C Pappas, and
R G Hanson, and
M Peters, and
M I Avigan, and
J G Waggoner, and
E A Jones, and
L B Seeff
September 1991,
Digestive diseases and sciences,
J H Hoofnagle, and
G L Davis, and
S C Pappas, and
R G Hanson, and
M Peters, and
M I Avigan, and
J G Waggoner, and
E A Jones, and
L B Seeff
July 2002,
Zhonghua yi xue za zhi,
J H Hoofnagle, and
G L Davis, and
S C Pappas, and
R G Hanson, and
M Peters, and
M I Avigan, and
J G Waggoner, and
E A Jones, and
L B Seeff
December 1995,
Annals of internal medicine,
J H Hoofnagle, and
G L Davis, and
S C Pappas, and
R G Hanson, and
M Peters, and
M I Avigan, and
J G Waggoner, and
E A Jones, and
L B Seeff
September 2018,
The Journal of dermatological treatment,
J H Hoofnagle, and
G L Davis, and
S C Pappas, and
R G Hanson, and
M Peters, and
M I Avigan, and
J G Waggoner, and
E A Jones, and
L B Seeff
January 1990,
Journal of hepatology,
J H Hoofnagle, and
G L Davis, and
S C Pappas, and
R G Hanson, and
M Peters, and
M I Avigan, and
J G Waggoner, and
E A Jones, and
L B Seeff
June 2017,
Rhinology,
J H Hoofnagle, and
G L Davis, and
S C Pappas, and
R G Hanson, and
M Peters, and
M I Avigan, and
J G Waggoner, and
E A Jones, and
L B Seeff
February 2002,
Hepatology (Baltimore, Md.),
J H Hoofnagle, and
G L Davis, and
S C Pappas, and
R G Hanson, and
M Peters, and
M I Avigan, and
J G Waggoner, and
E A Jones, and
L B Seeff
July 2006,
The Journal of infection,
